logo

For the Inventor, By the Inventor

Paris, France

Michael Gerard Tovey

USPTO Granted Patents = 20 

 

Average Co-Inventor Count = 2.1

ph-index = 8

Forward Citations = 186(Granted Patents)


Company Filing History:

goldMedal5 out of 5 
 
Pharma Pacific Pty. Ltd.
 patents
silverMedal5 out of 5 
 
Biomonitor Limited
 patents
bronzeMedal4 out of 4 
 
Le Centre Nationale De La Recherche Scientifique
 patents
4. 3 out of 3 
 
Svar Life Science Ab
 patents
5. 2 out of 2 
 
Medisup International, N.v.
 patents
6. 2 out of 152 
 
Medarex Inc.
 patents
7. 1 out of 1 
 
Laboratoire European De Biotechnologie S.a.
 patent
8. 1 out of 1 
 
Neutekbio Limited
 patent
9. 1 out of 338 
 
Agence Nationale De Valorisation De La Recherche (anvar)
 patents
10. 1 out of 5,089 
 
Centre National De La Recherche Scientifique
 patents
11. 1 out of 1 
 
Le Centre Nationale De La Recherche Scientifique (cnrs)
 patent
where one patent can have more than one assignee

Years Active: 1976-2025

Loading Chart...
Loading Chart...
20 patents (USPTO):Explore Patents
1. 12359195 - Secreted reporter-peptides for optimizing cell-based assays for analysis on immuno-assay platforms (2025-07-15),
2. 12025620 - System and products for improved quantification of ADCC and ADCP activity (2024-07-02),
3. 11280790 - System and products for improved quantification of ADCC activity (2022-03-22),
4. 10271539 - Assay-ready frozen cell and method for minimizing variability in the performance thereof (2019-04-30),
5. 9969801 - Cell, method and kit for conducting an assay for neutralizing antibodies (2018-05-15),
6. 9188580 - Gene reporter assay, kit, and cells for determining the presence and/or the level of a molecule that activates signal transduction activity of a cell surface protein (2015-11-17),
7. 8759091 - Gene reporter assay, kit and cells with improved sensitivity and/or specificity for determining the level of an extracellular signal (2014-06-24),
8. 8426123 - Method for conducting an assay for neutralizing antibodies (2013-04-23),
9. 7470536 - Gene reporter assay, kit, and cells for determining the presence and/or the level of a molecule that activates signal transduction activity of a cell surface protein (2008-12-30),
10. 7465451 - Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon (2008-12-16),
11. 7244818 - Interferon alpha responsive protein (2007-07-17),
12. 7179465 - Monoclonal antibodies against the interferon receptor, with neutralizing activity against type 1 interferon (2007-02-20),
13. 6787634 - Isolated peptide or polypeptide of the extracellular portion of the human interferon receptor (IFN-R). (2004-09-07),
14. 6660258 - Oromucosal cytokine compositions and uses thereof (2003-12-09),
15. 6475983 - Water-soluble polypeptides having a high affinity for &agr; and &bgr; interferons (2002-11-05),

Title: Michael Gerard Tovey: Innovator in Antibody-Mediated Therapeutics

Introduction

Michael Gerard Tovey is a distinguished inventor based in Paris, France, known for his significant contributions to the field of antibody-mediated therapies. With an impressive portfolio of 19 patents, Tovey has focused his research on enhancing the quantification of antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP), areas critical to the development of therapeutic antibodies.

Latest Patents

Among his latest innovations is a novel system and products for improved quantification of ADCC and ADCP activity. This invention introduces unique cells optimized for determining ADCC and ADCP activities in various samples. Another of Tovey's recent patents addresses the quantification of ADCC activity specifically. This patent details an engineered effector cell line that expresses the low-affinity Fc receptor, FcγR111a (CD16), which activates a NFAT responsive reporter gene upon ligation of the antibody bound to target cells. The innovative use of a synthetic chimeric promoter regulates the firefly luciferase (FL) gene, enhancing the assay's sensitivity and dynamic range while minimizing the interference from human serum.

Career Highlights

Throughout his career, Tovey has made notable advancements in therapeutic antibody mechanisms, spending significant time at companies such as Pharma Pacific Pty. Ltd. and Biomonitor Limited. His work has been instrumental in pushing the boundaries of current knowledge and methodologies within the pharmaceutical field.

Collaborations

Michael Gerard Tovey has collaborated with esteemed colleagues, including Christophe Lallemand and Francois Meyer, which has led to further development and refinement of his innovative systems and products. These collaborations have not only fostered a productive exchange of ideas but have significantly contributed to the success of his inventions.

Conclusion

Michael Gerard Tovey exemplifies the spirit of innovation in the biotechnology sector. His patents reflective of cutting-edge research and engineering provide invaluable tools for the quantification of therapeutic antibodies, bridging gaps in the understanding and application of ADCC and ADCP. His contributions continue to shape advancements in the field, impacting both research and clinical applications significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…